Summary
The CSF of Parkinson’s disease patients was shown to possess an antibody (IgG) which immunocytochemically reacts with dopamine cells in the substantia nigra of the rat. This dopamine neuron antibody (DNAb) was also identified in the CSF of patients with possible nigral degeneration. In contrast, control patients or patients with neurologic disease which is not associated with nigral pathology, did not possess the DNAb in their CSF.
The data is most consistent with a hypothesis which suggests that the DNAb represents a secondary autoinmune response to nigral degeneration. As such, the DNAb may be useful as a diagnostic marker for Parkinson’s disease and other disorders with nigral degeneration. Since nigral degeneration is thought to precede symptom expression by many years, the DNAb should theoretically be present in CSF prior to symptom expression and would thus represent an early, presymptomatic marker of Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bluestein HG (1984) Antineuronal antibodies in the pathogenesis of neuropsychiatric manifestations of systemic lupus erythematosus. In: Behan P, Spreafico F (eds) Neuroimmunology. Raven Press, New York, pp 157–165
Carvey PM, Kroin JS, Zhang TJ, O’Dorisio TM, Yaksch TL, McRae A, Dahlstrom A, Kao LC, Goetz CG, Tanner CM, Shannon KM, Klawans HL (1988) Biochemical and immunochemical characterization of ventricular CSF from Parkinson’s disease patients with adrenal medulla transplants. Neurology 38 [Suppl 1]: 144
Chapman J, Korczyn AD, Hareuveni M, Michaelson DM (1986) Antibodies to cholinergic cell bodies in Alzheimer’s disease. In: Fisher A, Hanin I, Lachman C (eds) Alzheimer’s and Parkinson’s disease. Strategies for research and development. Plenum Press, New York, pp 329–336
Filit HM, Luine V, Reisberg B, Amador R, McEwen BS, Zabriske JB (1985) Studies of the specificity of autobrain antibodies in Alzheimer’s disease. In: Hutton JT, Kenny AD (eds) Senile dementia. Alan R Liss, New York, pp 307–336
Franceschi M, Comola M, Nemni R, Pinto P, Iannaccone S, Smirne S, Canal N (1988) Neuron-binding antibodies in Alzheimer’s disease and Down’s syndrome. Neurology 38 [Suppl 1]: 285
Gaskin F, Kingsly BS, Fu SM (1987) Autoantibodies to neurofibrillary tangles and brain tissue in Alzheimer’s disease. Establishment of Epstein-Barr virus-transformed antibody-producing cell lines. J Exp Med 165: 245–250
Gonatas NK (1984) Immunohistopathology of experimental allergic encephalomyelitis. In: Behan P, Spreafico F (eds) Neuroimmunology. Raven Press, New York, pp 113–126
Hornykiewicz O (1979) Compensatory biochemical changes at the striatal dopamine synapse in Parkinson’s disease and limitations of L-dopa therapy. Adv Neurol 24: 275–281
Husby GL, van de Rijn I, Zabriskie JB, Abdin ZH, Williams RC (1976) Antibodies reacting with cytoplasm of subthalamic nuclei neurons in chorea and acute rheumatic fever. J Exp Med 144: 1094–1110
Husby GL, Davis LE, Wedege E, Kokmen E, Williams RC (1977) Antibodies to human caudate nucleus neurons in Huntington’s chorea. J Clin Invest 59: 922–932
Ishii T, Haga S (1976) Immunoelectron microscopic localization of immunoglobulins in amyloid fibrils of senile plaques. Acta Neuropathol 36: 243–249
Itagaki S, McGeer PL, McGeer EG (1987) HLA-DR reactive microglia in Parkinson’s disease. J Neuroimmunol 16 (1): 81
Johnson KP (1980) Cerebrospinal fluid and blood assays of diagnostic usefulness in multiple sclerosis. Neurology 30: 106–109
McFarlin DE (1984) Immunologic abnormalities associated with neurologic diseases. In: Behan P, Spreafico F (eds) Neuroimmunology. Raven Press, New York, pp 237–245
McFarlin DE, Strober W, Waldmann T (1972) Ataxia-telangiectasia. Medicine 51: 281–314
McRae-Degueurce A, Geffard M (1986 a) One perfusion mixture for immunocytochemical detection of noradrenaline, dopamine, serotonin and acetylcholine in the same rat brain. Brain Res 37: 217–219
McRae-Degueurce A, Gottfries CG, Karlsson I, Svennerholm L, Dahlstrom A (1986 b) Antibodies in the CSF of a Parkinson patient recognize neurons in rat mesencephalic regions. Acta Physiol Scand 126: 313–315
McRae-Degueurce A, Booj S, Haglid K, Rosengran L, Karlsson JE, Karlsson I, Wallin A, Svennerholm L, Gottfries C-G, Dahlstrom A (1987) Antibodies in cerebrospinal fluid of some Alzheimer’s disease patients recognize cholinergic neurons in the rat central nervous system. Proc Natl Acad Sci 84: 9214–9218
McRae-Degueurce A, Klawans FIL, Penn RD, Dahlstrom A, Tanner CM, Goetz CG, Carvey PM (1988 a) An antibody in the CSF of Parkinson’s disease patients disappears following adrenal medulla transplantation. Neurosci Lett 94: 192–197
McRae-Degueurce A, Rosengren L, Haglid K, Booj S, Gottfries CG, Granerus AC, Dahlstrom A (1988 b) Immunocytochemical investigations on the presence of neuron-specific antibodies in the CSF of Parkinson’s disease cases. Neurochem Res 13: 679–684
McRae A, Dahlstrom A, Klawans FIL, Goetz CG, Tanner CM, Penn RD, Carvey PM (1989) Adrenal medulla transplantation in Parkinson’s disease reduces the presence of a CSF antibody to the rat substantia nigra. Neurology 39 [Suppl 11: 364
Penn RD, Goetz CG, Tanner CM, Klawans HL, Shannon KH, Comella CL, Witt TR (1988) The adrenal medullary transplant operation for Parkinson’s disease: clinical observations in five patients. Neurosurgery 22: 999–1004
Rao N, Costa JL (1989) Recovery in non-vascular locked-in syndrome during treatment with sinemet. Brain Injury 3: 207–211
Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, Vicari AM (1988) Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318: 1012–1020
Solimena M, Folli F, Pozza G, De Camilli P (1989) Autoantibodies directed against GABAergic synapses in stiff-man syndrome. Neurology 39 [Suppl 1]: 384
Spencer PS, Nunn PB, Hugon J, Ludolph AC, Ross SM, Roy DN, Robertson RC (1987) Guam amyotrophic lateral sclerosis-parkinsonian-dementia linked to a plant excitant neurotoxin. Science 237: 517–522
P. M. Carvey et al.: Dopamine-neuron antibody in Parkinson’s disease
Tourtellotte WW, Potvin AR, Potvin HH, Ma BI, Baumhefner RW, Syndulko K (1980) Multiple sclerosis de novo CNS IgG synthesis: measurement, antibody profile, significance eradication, and problems. In: Bauer HJ, Poser S, Ritter G (eds) Progress in multiple sclerosis. Springer, Berlin Heidelberg New York, pp 106–110
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag/Wien
About this chapter
Cite this chapter
Carvey, P.M., Klawans, H.L., Kao, L.C., Dahlström, A., McRae, A. (1990). An antibody in the CSF of Parkinson’s disease patients: summary of data and potential role as a diagnostic marker. In: Dostert, P., Riederer, P., Strolin Benedetti, M., Roncucci, R. (eds) Early Markers in Parkinson’s and Alzheimer’s Diseases. New Vistas in Drug Research, vol 1. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9098-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9098-2_5
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-9100-2
Online ISBN: 978-3-7091-9098-2
eBook Packages: Springer Book Archive